Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples

Kriegsmann, Katharina; Flechtenmacher, Christa; Heil, Jörg; Kriegsmann, Jörg; Mechtersheimer, Gunhild; Aulmann, Sebastian; Weichert, Wilko; Sinn, Hans‐Peter; Kriegsmann, Mark

doi:10.3390/ijms21176407

Cited by 21 publications

(19 citation statements)

References 37 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SOX10 expression may lead to confusion in diagnosis but many studies have proven that breast carcinomas, particularly basal-like, triple-negative phenotypes, are also labeled by SOX10 [19]. This study is the continuation of a similar study conducted by Katharina et al in Germany [20].…”

Section: Discussionmentioning

confidence: 54%

Expression of SOX10 in Triple-Negative Breast Carcinoma in Pakistan

Ali¹,

Rathore²,

Rafique³

et al. 2022

Cureus

View full text Add to dashboard Cite

BackgroundThe term triple-negative breast cancer (TNBC) refers to a particular class of aggressive, poorly differentiated neoplasms that show the absence of estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2) antibodies. SOX10 (SRY-related HMG-box 10) is a nuclear transcription factor that is commonly used to identify cancers of neural origin, but it has recently been linked to TNBC. The purpose of this study is to determine SOX10 expression in TNBC, its association with tumor grade for molecular categorization, and to determine the diagnostic significance of SOX10 in TNBC at the metastatic site in the case of an unknown primary. MethodologySOX10 was used to stain a tissue microarray of 100 patients. According to the tumor grade, SOX10 staining was classified as negative (<1%), patchy (1-10%), focal (10-70%), and diffuse (70-100%). SPSS version 22 (IBM Corp., Armonk, NY, USA) software was used to conduct the statistical analysis. ResultsThe expression of SOX10 regarding positivity and intensity was higher in high-grade tumors than in intermediate-grade tumors (p = 0.001 and p = 0.007, respectively). ConclusionsSOX10 is a reliable novel marker for the diagnosis of TNBC and has diagnostic utility in the unknown primary at the metastatic site.

show abstract

Section: Discussionmentioning

confidence: 54%

Expression of SOX10 in Triple-Negative Breast Carcinoma in Pakistan

Ali¹,

Rathore²,

Rafique³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…While others have found greater sensitivities using GATA3, this study demonstrated mammaglobin's increased ability to identify non-luminal tumors from 23% to 48%, which is much higher than previously reported by Liu et al [30] (35% of ER negative tumors), Ordonez and Sahin [31] (18% of TNBCs), and Krings et al [31] (26% of TNBCs). Still, given that either GATA3 or mammaglobin fail to identify more than 50% of TNBCs these markers should be supplemented with markers speci c for TNBC, such as Sry-related HMG box (SOX) 10, which is found in 40%-70% of TNBCs and appears to be expressed in tumors that are negative for GATA3 [32][33][34]. More recently, it was demonstrated that adding SOX10 improved the sensitivity of the markers in metastatic breast cancer (sensitivity = 0.89), metastatic TNBC (0.78), and primary TNBC (0.78) [35].…”

Section: Discussionmentioning

confidence: 99%

Characterization of GATA3 and Mammaglobin in breast tumors from African American women

Ricks-Santi

Fredenburg

Rajaei

et al. 2023

Preprint

View full text Add to dashboard Cite

GATA3 and Mammaglobin are often used in the clinic to identify metastases of mammary origin due to their robust and diffuse expression in mammary tissue. However, the expression of these markers has not been well characterized in tumors from African American women. The goal of this study was to characterize and evaluate the expression of GATA3 and mammaglobin breast tumors from African American women and determine their association with clinicopathological outcomes including breast cancer subtypes. Tissue microarrays (TMAs) were constructed from well preserved, morphologically representative tumors in archived formalin-fixed, paraffin-embedded (FFPE) surgical blocks from 202 patients with primary invasive ductal carcinoma. Mammaglobin, and GATA3 expression was assessed using immunohistochemistry (IHC). Univariate analysis was carried out to determine the association between expression of GATA3, mammaglobin and clinicopathological characteristics. Kaplan-Meier estimates of overall survival and disease-free survival were also plotted and a log-rank test performed to compare estimates among groups. GATA3 expression showed statistically significant association with lower grade (p<0.001), ER-positivity (p<0.001), PR-positivity (p<0.001), and the luminal subtype (p<0.001). Mammaglobin expression was also significantly associated with lower grade (p=0.031), ER-positivity (p=0.007), and PR-positivity (p=0.022). There was no association with recurrence-free or overall survival. Our results confirm that GATA3 and mammaglobin demonstrate expression predominantly in luminal breast cancers from African American women. Markers with improved specificity and sensitivity are warranted given the high prevalence of triple negative breast cancer in the group.

show abstract

“…In such cases, SOX-10 may be helpful. 28 Primary small cell carcinoma of the breast is extremely rare. The negative expression of ER and PR in the small cell carcinoma favors metastasis since the very rare examples of primary small cell carcinoma of the breast express these markers in 33% to 50% of cases.…”

Section: Discussionmentioning

confidence: 99%